Universe Pharmaceuticals Inc (UPC) Gross Profit Margin starting from the fourth quarter 2025 to fourth quarter 2023, Profitability Trends and Ranking, Fundamental Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Gross Margin
• EBITDA Margin
• Operating Margin
• Net Margin
• Pre-Tax Margin
• Effective Tax Rate
• Free Cash Flow Margin
• Cash Flow Margin
Universe Pharmaceuticals Inc  (NASDAQ: UPC)


Universe Pharmaceuticals Inc's Gross Profit Margin by quarter

Trends, Rankings, Statistics


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

UPC Gross Profit Margin (Sep 30 2025)
Q4 		0
Q3 		0
Q2 		0
Q1 		(Sep 30 2023)
Q4
Y / Y Revenue Change 55175.24 %
Seq. Revenue Change -
Revenue In Millions $17,858.73
Gross Profit Margin 35.28 %
Gross Profit Margin Total Ranking # 2345
Gross Profit In Millions $6,301.17
Y / Y Gross Profit Change 60986.64 %
Seq. Gross Profit Change -


Commenting fourth quarter 2025 Gross Profit Margin



Observing fourth quarter 2025 results within Major Pharmaceutical Preparations industry 130 other companies have achieved higher Gross Profit Margin. While Gross Profit Margin overall ranking has deteriorated relative to the three months before, from to 2345.
Learn about Gross Margin
UPC's Gross Profit Margin fourth quarter 2025 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 131
Healthcare Sector # 378
Overall # 2324

Gross Profit Margin Statistics
High Average Low
54.53 % 43.63 % 31.93 %
(Sep 30 2022)   (Sep 30 2023)


UPC Gross Income Trends • More of UPC's Profitabilty Ratios • UPC Stock Quotes and Charts


Other Gross Profit Margin Profitability Ratios
UPC's Cumulative Gross Profit Margin
Major Pharmaceutical Preparations Industry Gross Profit Margin Trends and Statistics
Healthcare Sector Gross Profit Margin Statistics
Gross Profit Margin Profitability Trends for overall market
UPC's Gross Profit Margin Profitability versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Gross Profit Margin
Lowest Ranking Gross Profit Margin
Gross Profit Margin Profit Margin for UPC's Competitors
Gross Profit Margin Profit Margin for Universe Pharmaceuticals Inc's Suppliers
Gross Profit Margin Profit Margin for UPC's Customers

You may also want to know
UPC's Annual Growth Rates UPC's Profitability Ratios UPC's Asset Turnover Ratio UPC's Dividend Growth
UPC's Roe UPC's Valuation Ratios UPC's Financial Strength Ratios UPC's Gross Profit Growth
UPC's Roa UPC's Inventory Turnover Ratio UPC's Growth Rates UPC's Dividend Comparisons


Companies with similar Gross Profit Margin in the quarter ending Sep 30 2025, within Major Pharmaceutical Preparations Industry Gross Profit MarginSep 30 2025 MRQ Gross ProfitSep 30 2025 MRQ Revenue
Ardelyx inc   96.39 %$ 106.347  Millions$ 110.329  Millions
Rafael Holdings Inc  96.25 %$ 0.231  Millions$ 0.240  Millions
Liquidia Corporation  95.78 %$ 52.047  Millions$ 54.342  Millions
Zevra Therapeutics Inc   95.25 %$ 24.825  Millions$ 26.063  Millions
Karyopharm Therapeutics Inc   95.20 %$ 41.931  Millions$ 44.044  Millions
Vanda Pharmaceuticals Inc   94.75 %$ 53.304  Millions$ 56.258  Millions
Avadel Pharmaceuticals Plc  94.69 %$ 73.351  Millions$ 77.467  Millions
Gyre Therapeutics Inc   94.67 %$ 28.936  Millions$ 30.564  Millions
Kyntra Bio Inc   94.61 %$ 1.018  Millions$ 1.076  Millions
Bridgebio Pharma Inc   94.56 %$ 114.137  Millions$ 120.700  Millions
Rigel Pharmaceuticals Inc  93.16 %$ 64.709  Millions$ 69.462  Millions
Axsome Therapeutics Inc   93.03 %$ 159.080  Millions$ 170.992  Millions
Ligand Pharmaceuticals Incorporated  92.99 %$ 107.364  Millions$ 115.461  Millions
Regeneron Pharmaceuticals Inc   92.52 %$ 3,473.300  Millions$ 3,754.300  Millions
Acadia Pharmaceuticals Inc   92.23 %$ 256.986  Millions$ 278.633  Millions
Arcutis Biotherapeutics Inc   91.25 %$ 90.534  Millions$ 99.219  Millions
Longeveron Inc   91.24 %$ 0.125  Millions$ 0.137  Millions
Kalvista Pharmaceuticals Inc   91.00 %$ 12.460  Millions$ 13.692  Millions
Supernus Pharmaceuticals inc   90.13 %$ 173.138  Millions$ 192.103  Millions
Rhythm Pharmaceuticals Inc   89.28 %$ 45.799  Millions$ 51.298  Millions
Cormedix Inc   89.26 %$ 93.081  Millions$ 104.275  Millions
Uniqure N v   89.25 %$ 3.303  Millions$ 3.701  Millions
Urogen Pharma Ltd   88.97 %$ 24.204  Millions$ 27.204  Millions
Aurinia Pharmaceuticals Inc   88.87 %$ 65.291  Millions$ 73.468  Millions
Kiniksa Pharmaceuticals International Plc  88.80 %$ 160.598  Millions$ 180.855  Millions
Bioxcel Therapeutics Inc   88.78 %$ 0.087  Millions$ 0.098  Millions
Amicus Therapeutics inc   88.73 %$ 149.594  Millions$ 168.594  Millions
Blue Water Vaccines Inc  88.55 %$ 0.269  Millions$ 0.304  Millions
Cumberland Pharmaceuticals Inc   88.08 %$ 7.304  Millions$ 8.292  Millions
Ocular Therapeutix Inc   87.80 %$ 12.770  Millions$ 14.544  Millions




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.